p300 degrader / AbbVie - LARVOL DELTA

Discovery of a paralog selective p300 protein degrader with potent anti-cancer activity in hematological malignancies (AACR 2026) - "AbbVie participated in the interpretation of data, review, and approval of the publication. No honoraria or payments were made for authorship."

Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology • CREBBP • EP300